Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized placebo-controlled venetoclax plus induction and consolidation chemotherapy in newly diagnosed AML
NL-OMON59474Phase 3Recruiting
- Sponsor
- University Hospital Ulm
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute myeloid leukemia (AML) comparing Venetoclax arm with Placebo arm (2 arms). Primary endpoint: Event-free survival. Started Jul 2025; status: recruiting.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NL-OMON59474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59474.